|
Orthologous residues
|
|
ITK (human): Y512‑p, ITK (mouse): Y517‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, peptide sequencing, phospho-antibody, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
Jurkat (T lymphocyte) [ITK (human)], Jurkat (T lymphocyte) [Lck (human)], SF9 [ITK (human)], SF9 [Lck (human)]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, insect
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Lck (human)
|
genetic transfer of wild-type enzyme, genetic transfer of dominant-negative enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
anti-CD3
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation
|
